NDOH circular on Lamivudine
Lamivudine_Stock Availability_040619 (002)
The case for including more babies and young children in medical research
All medicines and treatments have to go through lengthy safety and efficacy testing, but this is particularly tricky – and often delayed – for one important age group. Elna Schütz explores the complexities of conducting clinical trials involving babies, and why those complexities are worth grappling with.
Health policy trailblazer Precious Matsoso credits patience, keeping her cool, and The Beatles
Precious Matsoso tells Biénne Huisman how, over three decades, she helped shape some of the most consequential health policy negotiations in South Africa and in global governance. She also shares memories about her Soweto childhood filled with music, science, and political uprisings.
Is Aspen betting on the right HIV prevention product?
Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.
Leave a Reply